Cartalax (20mg)

Description

What is Cartalax?

Cartalax (Ala‑Glu‑Asp / AED) is a synthetic tripeptide from the Khavinson series of “peptide bioregulators,” presented as the short analog of a larger cartilage‑tissue bioregulator. The Russian literature reports effects on chondrocyte function, cartilage matrix synthesis, and joint inflammation markers in preclinical and early‑clinical gerontology research.

Mechanism of Action

• Proposed epigenetic modulation via promoter‑region DNA binding (Khavinson model)
• Reported enhancement of chondrocyte proliferation and type‑II collagen synthesis in cell culture
• Attenuated inflammatory markers in rodent osteoarthritis models
• Putative restoration of circadian rhythms in aged animals (class effect of bioregulator tripeptides)

Compound Properties

• Sequence: Ala‑Glu‑Asp (AED)
• Molecular formula: C₁₂H₁₉N₃O₈
• Molecular weight: ~333.3 g/mol
• Form: Lyophilized powder
• Unit size: 20 mg / vial
• Source: Solid‑phase peptide synthesis; ≥98% purity by HPLC

Research‑Reference Dosing

Published research‑reference ranges:

• Khavinson lab publications in Bulletin of Experimental Biology and Medicine, Advances in Gerontology: chondrocyte and cartilage‑culture data.
• Peer‑reviewed Western‑journal and clinical trial data for Cartalax specifically is very limited.

Research Findings

• Enhanced cartilage matrix synthesis markers in cell culture (Khavinson group)
• Claimed improvement in joint endpoints in Russian clinical pilots
• Evidence base is thin and Russian‑dominated; independent Western replication is absent

Known Side Effects Reported in Research/Trials

• Generally well tolerated in published cohorts
• Rare injection‑site reactions
• Long‑term human safety data is unavailable

Storage & Handling

• Lyophilized (unreconstituted) vials: store at −20°C long‑term; short‑term 2–8°C acceptable.
• After reconstitution with bacteriostatic or sterile water: store at 2–8°C; use within 14–28 days per standard peptide stability guidance.
• Protect from light, heat, and repeated freeze‑thaw cycles. Handle in a sterile laboratory environment.

Certificate of Analysis

A Certificate of Analysis (COA) confirming identity and purity by HPLC / MS is available upon request. Contact Lonestar Peptides for lot‑specific documentation.

Summaries reference peer‑reviewed preclinical and clinical literature available as of early 2025. Newer findings may not be reflected. Researchers should consult current literature and conduct their own due diligence. Lonestar Peptides makes no claim of therapeutic benefit.